BTK-Inhibition Enhances TLR-7-Mediated Interferon-Alpha Production in pDCs by Blocking the Inhibitory BDCA-2 Pathway

IF 4.5 3区医学 Q2 IMMUNOLOGY

European Journal of Immunology Pub Date : 2025-02-24 DOI:10.1002/eji.202450985

Laura Ceglarek, Ramona Gerhards, Vinicius Boldrini, Christian Wichmann, Anneli Peters, Edgar Meinl

引用次数: 0

Abstract

In pDCs, BTK-inhibition (BTKi) blocks the IFN-α production via TLR-9, but not via TLR-7. Upon TLR-7 stimulation, BTKi enhances the production of IFN-α by blocking the inhibitory BDCA-2 pathway. This might explain partially the failure of BTKi in SLE and is of interest for BTKi trials in multiple sclerosis.

Abstract Image

查看原文本刊更多论文

在 pDCs 中，BTK 抑制剂（BTKi）能阻止通过 TLR-9 而非 TLR-7 产生 IFN-α。在 TLR-7 刺激下，BTKi 会通过阻断抑制性 BDCA-2 通路来增强 IFN-α 的产生。这可能部分解释了 BTKi 在系统性红斑狼疮中的失败，并对 BTKi 在多发性硬化症中的试验具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Immunology 医学-免疫学

CiteScore

8.30

自引率

3.70%

发文量

224

审稿时长

2 months

期刊介绍： The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.